



Intuitive Investments Group plc ("IIG" or the "Company")

Portfolio company BioQ Pharma receives CE mark

EU approval for BioQ's next generation medication dispenser

Intuitive Investments Group plc (AIM: IIG), a closed-end investment company focussed on the life sciences sector, announces that its portfolio company, BioQ Pharma Incorporated ("BioQ"), has received CE mark approval for its single-use medication dispenser, the *OneDose ReadyfusOR Gen2*.

The OneDose ReadyfusOR Gen2 is the second generation of BioQ's original OneDose ReadyfusOR infusion system and was developed to further improve patient convenience. The new system is smaller and lighter than the original product. For the full announcement, visit: https://bioqpharma.com/news/article 20210127

BioQ is a well-established, commercial-stage, medical device and pharmaceutical company, addressing the infusible drugs market. BioQ's proprietary *Invenious*TM platform comprises a "connect-and-go" drug-device system combination, which can be utilised to improve the delivery of infusible medicines. The key benefits of the platform include reduced cost and complexity compared to current infusion techniques. Further information on BioQ can be found at the company's website: www.biogpharma.com.

On 21 January 2021, IIG announced its investment of US\$1 million by way of unsecured convertible loan notes in BioQ, the Company's second investment from its pipeline of opportunities following its successful IPO in December 2020.

For further information, please contact:

Intuitive Investments Group plc David Evans	<u>www.iigplc.com</u> Via Walbrook PR
Strand Hanson Limited – Nominated Adviser James Harris / James Dance / James Bellman	+44 (0)20 7409 3494
Turner Pope Investments (TPI) Ltd – Broker Ben Turner / James Pope / Andrew Thacker	+44 (0)20 3657 0050
Walbrook PR Limited – Media & Investor Relations Paul McManus	+44 (0)20 7933 8780 or <u>intuitive@walbrookpr.com</u> +44 (0) 7980 541 893

About Intuitive Investments Group plc

The Company is a newly established investing company, seeking to provide investors with exposure to a portfolio concentrating on fast growing and/or high potential Life Sciences businesses operating predominantly in the UK, continental Europe and the US, utilising the Board's experience and in particular that of the Chairman, David Evans, to seek to generate capital growth over the long term for shareholders.